Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen 3Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Amgen 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

3Q Revenues: $3.9 billion (+7%)

3Q Earnings: $1.2 billion (earnings were $201 million in 3Q07)

YTD Revenues: $11.3 billion (+3%)

YTD Earnings: $3.2 billion (+39%)

Comments: Sales of Aranesp were up 3% to $845 million. Sales of Epogen increased 5% to $634 million. Combined sales of Neulasta and Neupogen were up 8% to $1.2 billion. Sales of Enbrel were $893 million (+9%). Sales of Sensipar increased 32% to $161 million. R&D expenses were $729 million in the quarter (-6%). Earnings in 3Q07 were negatively impacted by $590 million of acquired in-process R&D related to the acquisitions of Alantos Pharmaceutical Holdings and Ilypsa, Inc., as well as $293 million of restructuring charges.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters